Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GW PHARMACEUTICALS PLC (GWPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/17/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
05/05/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
05/05/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
05/05/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
05/05/2021 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
05/05/2021 8-K Quarterly results
05/05/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/30/2021 10-Q Quarterly Report for the period ended March 31, 2021
04/30/2021 10-K/A Annual Report for the period ended December 31, 2020 [amend]
04/28/2021 GN GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation
04/23/2021 8-K Quarterly results
04/23/2021 GN GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
04/20/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2021 8-K Quarterly results
04/20/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
04/20/2021 GN GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex
04/14/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/14/2021 8-K Quarterly results
03/25/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/23/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/23/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
03/23/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/23/2021 8-K Quarterly results
03/15/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/15/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
03/10/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
03/04/2021 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
02/26/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
02/26/2021 10-K Annual Report for the period ended December 31, 2020
02/26/2021 GN GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex
02/24/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
02/24/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
02/23/2021 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy